TRACON Pharmaceuticals Appoints Mark Wiggins as Chief Business Officer
May 30, 2018 at 08:00 am EDT
Share
TRACON Pharmaceuticals announced that it has appointed Mark Wiggins as Chief Business Officer, effective immediately. Mr. Wiggins has over 30 years of business development and commercial experience in senior roles in the biotech industry. He will be responsible for corporate and business development and report directly to Charles Theuer, M.D., Ph.D., President and CEO of TRACON. Previously, Mr. Wiggins served as Senior Vice President of Corporate and Business Development at Elcelyx Therapeutics, and Chief Business Officer at Mpex Pharmaceuticals. Mr. Wiggins currently serves on the board of directors of Zogenix and SelectION.
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Companyâs clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.
TRACON PHARMACEUTICALS, INC. 
